Overcoming Pediatric Iron Deficiency Anemia with IV Iron: Interprofessional Approaches to Integrating New Data, Using Novel Agents, and Optimizing Care
- Review the clinical gravity and foundational pathophysiology of iron deficiency anemia (IDA) in pediatric patients, with an emphasis on patient impact and the need for treatment.
- Evaluate the evolving clinical trial evidentiary base for intravenous (IV) iron as IDA management in pediatric patients, including a summary of recent FDA approvals and updated label indications for IV iron therapies.
- Discuss practical aspects of IV iron usage in the pediatric setting, including appropriate dosing, safety considerations, and clinician adherence to evidence-based IDA treatment standards.
- Use a real-world, case-based format to design evidence-supported strategies for recognizing, diagnosing, treating, and evaluating IDA in pediatric patients, focusing on the interpolation of IV iron into the management paradigm.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
5 min Welcome and Introductions/Pre-test
10 min Formative Foundations: The Epidemiology, Pathophysiology, and Clinical Gravity of Pediatric Iron Deficiency Anemia
25 min A Whole New World in Pediatric IDA Management: The Arrival of Intravenous Iron Products in the Paradigm
15 min Interprofessional Insights: Practical Principles for Improving Pediatric IDA Outcomes with IV Iron
5 min Conversations with the Experts and Q&A/Post-test
Jacquelyn M. Powers, MD, MS
Assistant Professor of Pediatrics
Associate Chief, Pediatric Hematology
Baylor College of Medicine
Texas Children's Cancer and Hematology Centers
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Caroline Heyrend, PharmD, BCPPS–has disclosed that she receives salary/employment from Intermountain Healthcare - Primary Children's Hospital.
Jacquelyn M. Powers, MD, MS–has disclosed that she was an advisor or consultant to Pharmacosmos, LLC, ending in 11/2021. She also received other financial or material support from Women's Health Research Collaborative on the Advisory Committee.
Information to come
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-022-H01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 ICPE
- 1.00 Participation